Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study
Annals of Neurology · 2026-10 · 100 (4) · 788-792
DOI: 10.1002/ana.78286 ↗At a glance
Kohortenstudie in Annals of Neurology, published online on 2026-06-17. Written by Thomas Frisell and 2 co-authors. Institution: Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. Major MEDLINE topics: Rituximab, Antibodies, Monoclonal, Humanized, Multiple Sclerosis, Immunologic Factors. Cited 5 times so far (Crossref); 15 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies (DMTs) between 2014 and 2025. Infection outcomes included serious infections, hospital‐diagnosed infections, and antibiotic use, and relapse risk was assessed as a marker of efficacy. Both rituximab and ocrelizumab were associated with higher infection rates than other DMTs, while relapse rates were substantially lower. Infection and relapse risks were similar between rituximab and ocrelizumab. ANN NEUROL 2026;100:788–792
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Academic Specialist Clinic, SLSO and Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.
ORCID profiles: Thomas Frisell, Fredrik Piehl
Cite
APA
Frisell, T., Hedberg, S., & Piehl, F. (2026). Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study. Annals of Neurology, 100(4), 788-792. https://doi.org/10.1002/ana.78286
Vancouver
Frisell T, Hedberg S, Piehl F. Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study. Annals of Neurology. 2026;100(4):788-792. doi:10.1002/ana.78286
BibTeX
@article{Frisell2026,
author = {Frisell, Thomas and Hedberg, Sebastian and Piehl, Fredrik},
title = {Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study},
journal = {Annals of Neurology},
year = {2026},
volume = {100},
number = {4},
pages = {788--792},
doi = {10.1002/ana.78286}
}
EUVIMED